Glenmark launches sacubitril+valsartan tablets in India to treat heart failure 

Glenmark Pharma has launched the sacubitril + valsartan tablets in India for the treatment of heart failure. Marketed under the brand name Sacu V, it must be taken twice daily under doctor’s prescription. Its approved indication is to reduce the risk of cardiovascular-related deaths and hospitalisations for patients with chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF), a company statement notified.

The sacubitril+valsartan combination belongs to the class Angiotensin Receptor Neprilysin Inhibitor (ARNI). These molecules have two therapeutic targets in the treatment of heart failure: the Natriuretic Peptide (NP) system for sacubitril and Renin Angiotensin System (RAS) for valsartan. The use of sacubitril+valsartan has an established role in treatment of patients with heart failure with reduced ejection fraction (HFrEF) and has been endorsed by the latest heart failure treatment guidelines in Europe and the United States (US), the statement said.

Glenmark’s Sacu V is priced at Rs 19 per tablet for a dose of 50 mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100 mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200 mg (sacubitril 97 mg + valsartan 103 mg), the statement concluded.